Views
4 years ago

70 - PR Papaleo - Octubre 2011

  • Text
  • Hypofunction
  • Antipsychotics
  • Nmda
  • Nmda
  • Prefontal
  • Trabajo
  • Memoria
  • Esquizofrenia
  • Alteraciones
  • Pacientes
  • Prefrontal
  • Corteza
  • Cognitivos
  • Enfermedad
  • Trastornos
  • Receptores
  • Psico
Alteración de la memoria de trabajo en la esquizofrenia

Dr. Pedro Ricardo

Dr. Pedro Ricardo Papaleo Charney, Josep Coyle y Charles N e m e r o f f. A m e r i c a n C o l l e g e o f Neuropsychopharmacology 2002; Schizophrenia and related disorders. Weinberger. Cap 48;657-669. Goldman-Rakic P: Working Memory Dysfunction in Schizophrenia. J Neuropsychiatry Clin Neurosciences 1994; 6: 348-357. Green M, Marshall Jr B, Wirshing W, Ames D, Marder S, y colds: Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia? Am J Psychiatry 1997; 154: 799-804. Green M: What are the functional concequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330. Javitt, D. C. y Coyle, J. T. Decoding schizophrenia.Scientific American ,2004.290, 48-55. Javitt, D. C. et al. Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery, 2008. 7, 68-83. Kapur, S. et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first episode schizophrenia. American Journal of Psychiatry,2000.157, 514-520. Kapur, S. y Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry ,1996 153, 466-476. Kapur, S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003; 160(1): 13-23. Kraepelin Emil: La Demencia Precoz (1ra Parte). Buenos Aires, Polemos, 1996. Laruelle, M. et al..Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of the New York Academy of Sciences,20031003, 138-158. Lewis, D. A. et al. Cortical inhibitory neurons and schizophrenia. NatureReviews Neuroscience, 2002. 6, 312-324. Lewis, D. A. y Levitt, P. Schizophrenia as a disorder of neurodevelopment. Annual Review ofNeuroscience,2002. 25, 409-432. Liddle, P. et al. (1994). Syndromes of schizophrenia. Classic literature. British Journal of Psychiatry,1994.165, 721-727. Lisman, J.E., Coyle, J.T., Green, R.W., Javitt, D.C., Benes, F.M., Heckers, S et al. Circuitbased framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008; 31 (5): 234-242. Lieberman, J. A. et al. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl), 1987.91, 415- 433. McGuire, P., Howes, O.D., Stone, J., Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol.Sci. 2008; 29 (2): 91-98. Meltzer H, Mc Gurk S: The Effects of Clozapine, Risperidone and Olanzapine on Cognitive Function in Schizophrenia. Schizophr Bull 1999; 25 (2): 233-255. Peralta, V. y Cuesta, M. J. (1995). Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models. American Journal of Psychiatry ,1995.152, 1450-1457. Purdon S, Jones B, Stip E, Labellie A, Addington D, y cols: Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment With Olanzapine, Riaperidone, or Holaperidol. Arch Gen Psychiatry 2000; 57: 249-258. Sambataro F, Blasi G, Fazio L, Caforio G, Taurisano P, Romano R, Di Giorgio A, Gelao B, Lo Bianco L, Papazacharias A, Popolizio T, Nardini M, Bertolino. Treatment with Olanzapine is Associated with Modulation of the Default Mode Network in Patients with Schizophrenia. Neuropsychopharmacology. 2009 Dec 2. Spitzer M: The Psychopathology, Neuropsychology, and Neurobiology of associative and working menory in Schizophrenia.Eur Arch Psychiatry Clin Neurosci 1993; 243: 57- 70. Tsai, G. y Coyle, J. T. Glutamatergic mechanisms in schizophrenia.Annual Review of Pharmacologyand Toxicology.2002, 42, 165- 179. Weinberger D, Aloia M, Goldbreg T, Berman K: The Frontal Lobes and Schizophrenia. J Neuropsychiatry Clin Neurosci 1994, 6: 419- 427. .Weinberger, D. R. y Berman, K. F. (1988). Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. SchizophreniaBulletin,1988 14, 157-168. Weinberger, D. R. y Lipska, B. K. (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground.Schizophrenia Research, 1995.16, 87- 110. Weinberger, D. Schizophrenia and related disorders. Neuropshychofarmacology: The fifth generation of progress. American College of Neuropsychofarmacology 2002. Section V; 639-640 Zieher L.M, Brio M.C. Actualizacion en la patofisiologia de la esquizofrenia desde la perspectiva de la neurociencia de sistemas. Psicofarmacologia 2009;56:9-16. Editorial Sciens Zieher L.M, Brio M.C. y col..Tratado de Psicofarmacologia y Neurociencia. Volumen I. Esquizofrenia y otras psicosis. Neurobiologia y terapeuticas. 2009. Editorial Sciens. 28 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015